Insights

PTAB Institutes Separate IPR Proceedings Filed by Codefendants, Finding that the Later IPR Proceeding Was Not Barred by 35 U.S.C. § 325(d), <i>PTAB Litigation Blog</i>

PTAB Institutes Separate IPR Proceedings Filed by Codefendants, Finding that the Later IPR Proceeding Was Not Barred by 35 U.S.C. § 325(d), PTAB Litigation Blog

Visit the Jones Day PTAB Litigation Blog.

On January 19, 2017, the PTAB instituted inter partes review of U.S. Patent No. 8,822,438 ("the ’438 patent") filed by Wockhardt Bio AG ("Wockhardt") (IPR2016-01582).  The ’438 patent is owned by Janssen Oncology, Inc. ("Janssen") and is the subject of several ongoing inter partes reviews, one of which was filed by Amerigen Pharm., Inc. ("Amerigen") which was instituted on May 31, 2016 (IPR2016-00286).  The ’438 patent is also being asserted in several district court proceedings against Amerigen, Wockhardt and other defendants.

Read the full article at ptablitigationblog.com.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.